Vilma Graupner
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 8
- Cancer Immunotherapy and Biomarkers 6
- CAR-T cell therapy research 3
- Lung Cancer Research Studies 2
- HER2/EGFR in Cancer Research 2
-
- Immunotherapy and Immune Responses 2
- Co-authors
- Mark A. Socinski (4 shared papers)Ross A. Soo (4 shared papers)Tien Hoang (4 shared papers)Robert M. Jotte (4 shared papers)Toshiyuki Kozuki (4 shared papers)Daniil Stroyakovskiy (3 shared papers)Delvys Rodríguez‐Abreu (3 shared papers)Federico Cappuzzo (3 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)Annals of Oncology (2 papers)Journal of Thoracic Oncology (2 papers)The Journal of Clinical Pharmacology (1 paper)CPT Pharmacometrics & Systems Pharmacology (1 paper)
- Partner nations
- SwitzerlandUnited StatesJapan
In The Last Decade
Vilma Graupner
8 papers receiving 739 citations
Vilma Graupner's Hit Papers
Peers
Comparison fields: 5 of 40
- Oncology 588
- Pulmonary and Respiratory Medicine 283
- Immunology 114
- Cancer Research 46
- Radiology, Nuclear Medicine and Imaging 32
Countries citing papers authored by Vilma Graupner
This map shows the geographic impact of Vilma Graupner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vilma Graupner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vilma Graupner more than expected).
Fields of papers citing papers by Vilma Graupner
This network shows the impact of papers produced by Vilma Graupner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vilma Graupner. The network helps show where Vilma Graupner may publish in the future.
Co-authors
The 25 scholars most cited alongside Vilma Graupner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Hit paper breakdown → | 2020 | 420 |
| 2 | 2018 | 170 | |
| 3 | 2022 | 86 | |
| 4 | 2018 | 23 | |
| 5 | 2021 | 23 | |
| 6 | 2019 | 15 | |
| 7 | 2022 | 5 | |
| 8 | 2025 | 3 | |
| 9 | 2025 | 0 | |
| 10 | 2026 | 0 |
About Vilma Graupner
Vilma Graupner is a scholar working on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 10 papers that have together received 745 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), CAR-T cell therapy research (3 papers), Lung Cancer Research Studies (2 papers), Immunotherapy and Immune Responses (2 papers), HER2/EGFR in Cancer Research (2 papers), Lung Cancer Treatments and Mutations (1 paper), Radiopharmaceutical Chemistry and Applications (1 paper) and Breast Cancer Treatment Studies (1 paper). The work is most often cited by research in Oncology (588 citations), Pulmonary and Respiratory Medicine (283 citations), Immunology (114 citations), Cancer Research (46 citations) and Radiology, Nuclear Medicine and Imaging (32 citations). Vilma Graupner has collaborated with scholars based in Switzerland, United States and Japan. Frequent co-authors include Mark A. Socinski, Ross A. Soo, Tien Hoang, Robert M. Jotte, Toshiyuki Kozuki, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Federico Cappuzzo, Ihor Vynnychenko and Maen Hussein. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, The Journal of Clinical Pharmacology and CPT Pharmacometrics & Systems Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.